Julie Zhen Qin Wu

Array ( [id] => 12231948 [patent_doc_number] => 20180064811 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-08 [patent_title] => 'PHARMACEUTICAL COMBINATIONS COMPRISING CD33 ANTIBODIES AND DE-METHYLATING AGENTS' [patent_app_type] => utility [patent_app_number] => 15/819364 [patent_app_country] => US [patent_app_date] => 2017-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 11320 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15819364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300235 [patent_doc_number] => 20180201654 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => PEPTIDE INHIBITORS OF HAUSP DEUBIQUITINASE [patent_app_type] => utility [patent_app_number] => 15/727472 [patent_app_country] => US [patent_app_date] => 2017-10-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15727472 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15038727 [patent_doc_number] => 20190330368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => THERAPY FOR DRUG-RESISTANT CANCER BY ADMINISTRATION OF ANTI-HER2 ANTIBODY/DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/334008 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27619 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16334008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14564091 [patent_doc_number] => 20190209652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => MODULATING RESPONSES TO CHECKPOINT INHIBITOR THERAPY [patent_app_type] => utility [patent_app_number] => 16/335913 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14409 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702761 [patent_doc_number] => 20170362335 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => TEM-1 DIAGNOSTIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/684611 [patent_app_country] => US [patent_app_date] => 2017-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15684611 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12975901 [patent_doc_number] => 20170340717 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => MSI-SPECIFIC FRAMESHIFT PEPTIDES (FSP) FOR PREVENTION AND TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/663858 [patent_app_country] => US [patent_app_date] => 2017-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5130 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15663858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12049836 [patent_doc_number] => 20170326179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS' [patent_app_type] => utility [patent_app_number] => 15/655432 [patent_app_country] => US [patent_app_date] => 2017-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 28212 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15655432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12449277 [patent_doc_number] => 09982279 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-05-29 [patent_title] => Nucleic acid-guided nucleases [patent_app_type] => utility [patent_app_number] => 15/632001 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 31 [patent_no_of_words] => 37634 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15632001 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12546924 [patent_doc_number] => 10011849 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2018-07-03 [patent_title] => Nucleic acid-guided nucleases [patent_app_type] => utility [patent_app_number] => 15/631989 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 31 [patent_no_of_words] => 38427 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 153 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15631989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16353139 [patent_doc_number] => 10793640 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-06 [patent_title] => Monoclonal antibodies against HER2 epitope [patent_app_type] => utility [patent_app_number] => 15/627921 [patent_app_country] => US [patent_app_date] => 2017-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 18 [patent_no_of_words] => 28083 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15627921 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13702757 [patent_doc_number] => 20170362333 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/626709 [patent_app_country] => US [patent_app_date] => 2017-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15626709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12092557 [patent_doc_number] => 20170349650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'IMMUNOGLOBULINS WITH REDUCED AGGREGATION' [patent_app_type] => utility [patent_app_number] => 15/596867 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28671 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376392 [patent_doc_number] => 20200325234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => IMMUNE-BASED TREATMENT OF KRAS-VARIANT CANCER PATIENTS [patent_app_type] => utility [patent_app_number] => 16/096316 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15946153 [patent_doc_number] => 10660955 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-26 [patent_title] => Cancer methods [patent_app_type] => utility [patent_app_number] => 15/481018 [patent_app_country] => US [patent_app_date] => 2017-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 22 [patent_no_of_words] => 37683 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15481018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12217432 [patent_doc_number] => 20180055791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'LOW DOSAGE SEROTONIN 5-HT2A RECEPTOR AGONIST TO SUPPRESS INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 15/478437 [patent_app_country] => US [patent_app_date] => 2017-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 10536 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15478437 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757316 [patent_doc_number] => 20170204182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'VH-VL-INTERDOMAIN ANGLE BASED ANTIBODY HUMANIZATION' [patent_app_type] => utility [patent_app_number] => 15/475440 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 33046 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15475440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13425179 [patent_doc_number] => 20180264132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => Combined Tissue Resonance Suppression Therapy and Autologous Polyvalent Biological Vaccine [patent_app_type] => utility [patent_app_number] => 15/462857 [patent_app_country] => US [patent_app_date] => 2017-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15462857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963615 [patent_doc_number] => 20170267768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'Protein A Binding Polypeptides, Anti-EphA2 Antibodies and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/457857 [patent_app_country] => US [patent_app_date] => 2017-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 19830 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15457857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706286 [patent_doc_number] => 20170174785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/450509 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 25913 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15450509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866188 [patent_doc_number] => 20170233473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/445208 [patent_app_country] => US [patent_app_date] => 2017-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 62076 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15445208 [rel_patent_id] =>[rel_patent_doc_number] =>)